A dual GIP and GLP-1 receptor agonist designed to support research into metabolic regulation through complementary incretin signaling pathways.
Leave your email and our team will contact you about Tirzepatide.
These products are intended for research and laboratory use only. Not intended for human or veterinary use. Not for diagnostic or therapeutic procedures. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Estimate delivery times: 12-26 days (International), 3-6 days (United States).
A dual GIP and GLP-1 receptor agonist designed to support research into metabolic regulation through complementary incretin signaling pathways.
Key Benefits: Supports research into appetite regulation, satiety, glucose homeostasis, energy utilization, metabolic function, and body composition.
Tirzepatide is typically administered under medical supervision, with dosing protocols tailored to individual health goals and clinical evaluation.
A next-generation triple receptor agonist that activates GIP, GLP-1, and glucagon receptor for advanced metabolic research and multi-pathway metabolic optimization.
A synergistic triad (BPC-157 / TB-500 / GHK-Cu) designed to accelerate internal healing while simultaneously rejuvenating skin and soft tissue.
A synthetic fragment of Thymosin Beta-4 that regulates actin to promote cell migration, angiogenesis, and structural tissue repair.
A growth hormone-releasing hormone (GHRH) analog designed to support the body's natural production of growth hormone by stimulating the pituitary gland.
This website contains research compounds for laboratory use only
By entering this site, you confirm that:
Legal Notice: All products are for research use only and are not FDA-approved for human or veterinary use.